Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men

Endocrine Journal

Volumn 57, Issue 8, 2010, Pages 673-677

  Aoki, Kazutaka ^a,b   Miyazaki, Takashi ^b   Nagakura, Jo ^b   Orime, Kazuki ^b   Togashi, Yu ^b   Terauchi, Yasuo ^b  

^a YOKOSUKA KYOSAI HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

glucosidase inhibitor; Miglitol; Postprandial hyperglycemia

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; MIGLITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIET RESTRICTION; DOSAGE SCHEDULE COMPARISON; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; MEAL; NORMAL HUMAN; POSTPRANDIAL STATE; UPREGULATION; VOLUNTEER;

1-DEOXYNOJIRIMYCIN; ADULT; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; CROSS-OVER STUDIES; ENZYME INHIBITORS; FASTING; FOOD; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KINETICS; MALE;

EID: 77957734906     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K10E-064     Document Type: Article

References (15)

1. Macfarlane DP, Paterson KR, Fisher M (2007) Oral antidiabetic agents as cardiovascular drugs. Diabetes Obes Metab 9: 23-30.
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B (2006) Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972.
3. Aoki K, Kato H, Terauchi Y (2007) Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 54: 1009-1014.
4. Aoki K, Nakamura A, Ito S, Nezu U, Iwasaki T, Takahashi M, Kimura M, Terauchi Y (2007) Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract 78:30-33.
5. Aoki K, Nakajima S, Nezu U, Shinoda K, Terauchi Y (2008) Comparison of pre- vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients, Diabetes Obes Metab 10: 970-972.
6. Narita T, Katsuura Y, Sato T, Hosoba M, Fujita H, Morii T, Yamada Y (2009) Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 26:187-188.
7. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T (2008) Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 57:1299-1306.
8. Lee A, Patrick P, Wishart J, Horowitz M, Morley JE (2002) The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 4:329-335.
9. Hira T, Mochida T, Miyashita K, Hara H (2009) GLP-1 secretion is enhanced directly in the ileum, but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate in rats. Am J Physiol Gastrointest Liver Physiol 297: G663-671.
10. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408.
11. Terauchi Y, Takamoto I, Kubota N, Matsui J, Suzuki R, Komeda K, Hara A, Toyoda Y, Miwa I, Aizawa S, Tsutsumi S, Tsubamoto Y, Hashimoto S, Eto K, Nakamura A, Noda M, Tobe K, Aburatani H, Nagai R, Kadowaki T (2007) Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 117: 246-257.
12. Kadowaki T, Miyake Y, Hagura R, Akanuma Y, Kajinuma H, Kuzuya N, Takaku F, Kosaka K (1984) Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26:44-49.
13. Aoki K, Ito Y, Saito K, Shirakawa J, Togashi Y, Satoh K, Muraoka T, Shinoda K, Masuda K, Kimura M, Terauchi Y (2009) Comparison of pre- versus postmeal administration of voglibose in men with or without impaired glucose tolerance. Diabetes Res Clin Pract 83: e31-32.
14. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial: Lancet 359: 2072-2007.
15. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K (2009) Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373:1607-1614.